Navigation Links
Use of MarginProbe® in DCIS Patients Presented at San Antonio Breast Cancer Symposium
Date:12/8/2011

FRAMINGHAM, Mass., Dec. 8, 2011 /PRNewswire/ -- An analysis of the MarginProbe pivotal study for patients with ductal carcinoma in situ (DCIS) and invasive lobular carcinoma (ILC) were presented today during the 2011 CTRC-AACR San Antonio Breast Cancer Symposium.  The results were presented by Dr. Susan K. Boolbol, Chief, Division of Breast Surgery, Beth Israel Medical Center, New York, New York.  In patients with DCIS or ILC, adjunctive use of MarginProbe significantly improved surgical outcomes by increasing surgeons' ability to identify and immediately resect positive margins, reducing the number of patients requiring re-excision by 49% and 64% respectively.

"DCIS and ILC represent a particular challenge to the breast surgeon," said Dr. Boolbol.  "Current intraoperative techniques are sub-optimal, leading to re-excision rates as high as 40%, as reported in the literature.  These study results represent a tremendous opportunity for breast surgeons to improve the quality of care they offer their patients."

"These results further reinforce the evidence of MarginProbe's benefit in all disease types, including the most challenging DCIS and lobular cases.  These results mirror those seen in Germany in our post-market study," said Dan Levangie, CEO of Dune Medical Devices.  "Across multiple studies, in the U.S., Europe, and Israel, adjunctive use of MarginProbe has consistently led to a 50% reduction in the number of patients requiring re-excision surgery in all disease types."

About the MarginProbe System

The MarginProbe System enables real time detection of cancer at or near the surface of excised tissue specimens during surgery for breast cancer.  The simple and immediate assessment of the surgical margins allows surgeons to immediately excise additional tissue, potentially saving a second procedure.  The MarginProbe System is Dune's first commercial product and is commercially available in Europe.  The MarginProbe device is an investigational device in the U.S.

About Dune Medical Devices

Dune Medical Devices was founded in 2002 by Dr. Dan Hashimshony to realize the extraordinary medical potential of its proprietary tissue characterization technology.  Offering surgeons and radiologists the real time ability to identify cancerous tissues and react immediately, this technology holds the promise for a broad range of surgical and diagnostic applications. 

Dune Medical Devices is a privately held company financed by Apax Partners since 2004.  It has offices in the U.S., Israel, Germany and Switzerland.  For more information, please visit www.dunemedical.com   

Contact:
Michael Graffeo
Dune Medical Devices
Michael.graffeo@dunemedical.com 
(508) 620-2782


'/>"/>
SOURCE Dune Medical Devices
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MarginProbe® Pivotal Study Presented at San Antonio Breast Cancer Symposium
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. Many Heart Attack Patients Dont Get Best Emergency Treatment
10. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
11. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
Breaking Medicine News(10 mins):